Annals

Annals Meeting Reports (1)

Edited by Edited by Annals of the New York Academy of Sciences.
Explore the Table of Contents
Annals Meeting Reports (1)

Published: May 2011

Volume 1226

This Annals volume presents three scholarly meeting reports covering current stem cell research, the developing field of behavioral epigenetics, and the novel properites of pepducins--peptides that alter cell signaling.
Learn More

The New York Stem Cell Foundation’s “Fifth Annual Translational Stem Cell Research Conference” convened October 12–13, 2010 at the Rockefeller University in New York City. The conference attracted over 400 scientists, patient advocates, and stem cell research supporters from 16 countries. Compiled by young stem cell scientists, this meeting report summarizes the current groundbreaking progress in stem cell research.

Sponsored by The New York Academy of Sciences, The Warren Alpert Medical School of Brown University, and The University of Massachusetts, “Behavioral Epigenetics” was held October 29–30, 2010 at The University of Massachusetts Boston Campus Center, Boston, Massachusetts. The conference featured speakers and panel discussions exploring the emerging field of behavioral epigenetics, from basic biochemical and cellular mechanisms to the epigenetic modulation of normative development, developmental disorders, and psychopathology. The meeting report provides an overview of the research presented by leading scientists and lively discussion about the future of investigation at the behavioral epigenetic level.

At the Second Pepducin Science Symposium held in Cambridge, Massachusetts in November 2010, investigators working in G protein-coupled receptor GPCR research convened to discuss progress since last year’s inaugural conference. This meeting report summarizes the symposium proceedings that focused on increasing knowledge of the structure and function of this ubiquitous superfamily of membrane receptors and their potential modulation for disease treatment, and how GPCR mechanisms might be exploited to treat diseases with pepducins, novel synthetic lipopeptide pharmacophores that modulate heptahelical GPCR activity from inside the cell membrane.